Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Olivier Antoine M. Charmeil

CEOOlivier Antoine M. Charmeil

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

113.69B

Market cap113.69B

Price-Earnings ratio

19.47

Price-Earnings ratio19.47

Dividend yield

3.41%

Dividend yield3.41%

Average volume

2.37M

Average volume2.37M

High today

$47.68

High today$47.68

Low today

$46.88

Low today$46.88

Open price

$47.15

Open price$47.15

Volume

4.36M

Volume4.36M

52 Week high

$55.73

52 Week high$55.73

52 Week low

$43.32

52 Week low$43.32

SNY News

TipRanks 7h

Nurix Therapeutics: Buy Rating Backed by Advancing Bexobrutideg Program, Sanofi STAT6 Milestones, and Solid Cash Runway

Nurix Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the st...

TipRanks 10h

Balanced Risk-Reward Amid Promising Lunsekimig Data and Valuation Uncertainty Supports Hold Rating

Analyst Steve Scala of TD Cowen maintained a Hold rating on Sanofi, retaining the price target of $57.00. Unlock hedge fund-level data and powerful investing t...

TipRanks 1d

Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward

Analyst Kate Dellorusso from LifeSci Capital maintained a Buy rating on Upstream Bio, Inc. and keeping the price target at $42.00. Unlock hedge fund-level data...

Analyst ratings

75%

of 8 ratings

Buy

75%

Hold

25%

Sell

More SNY News

Benzinga 2d

From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker

Strong Outcomes In Asthma Study In the Phase 2b AIRCULES trial, lunsekimig met both its primary and key secondary endpoints, demonstrating statistically signif...

Seeking Alpha 2d

Sanofi’s lunsekimig hits primary and key secondary endpoints in phase 2 Asthma and CRSwNP trials

Sanofi’s (SNY) lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP, the company said on Tuesday. Lunsekimig,...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.